Discussing commercial use of Filspari (sparsentan) and Vanrafia (atrasentan) in IgAN

Executed on:May 16, 2025 2:00 PM EDT

Call Duration:30 minutes

Expert Profile

ExpertBlinded Expert

Institution: MontefioreMedical Director, Pediatric Nephrology at Montefiore Health System, Inc., Associate Professor of Pediatrics at the Albert Einstein College of Medicine & Visiting Assistant Professor at Rockefeller University
Manages 80 IgAN and 45 pMN patients
Involved in clinical and translational research studying factors leading to progression to end-stage kidney disease, including fibrosis and complement-mediated pathways in lupus nephritis. Clinical interests are polycystic kidney disease, lupus nephritis, genetic causes of stone disease, complement pathway defects, immune-mediated renal diseases and biomarkers of acute kidney injury with a research interest is in lupus nephritis.

Interview Goal

Discuss how endothelin A receptor agonists are being used in the commercial setting to treat IgAN

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.